***PKTX...ProtoKinetix files for patent protection
Post# of 88
(Total Views: 268)
Posted On: 02/11/2020 8:24:16 AM
***PKTX...ProtoKinetix files for patent protection for the use of AAGP® in transplant medicine..
Marietta, Ohio, February 11, 2020
....ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB
KTX) recently filed for patent protection for a new application of its AAGP® molecule.
During recent testing at The University of British Columbia, where photo receptors were transplanted into animal models, it was observed that AAGP® may have had a role in protecting xenografts and allografts from immune rejection from the host immune system, thereby helping the graft to survive and mature in the transplant recipient.
Immune rejection, leading to graft versus host disease (GVHD) is a primary concern present in almost all transplants, requiring the use of immunosuppressants such as cyclosporin, tacrolimus and rapamycin.
In addition to filing for patent protection, ProtoKinetix has started a major study at Dalhousie University to examine the effects of AAGP® in transplant medicine.
By protecting this technology, the Company is in a better position to move forward with its research in organ transplantation.
“We are pleased to protect this patent as we can now license the rights to other companies to develop different applications of the AAGP® lead compound,” said Clarence E. Smith, president and chief executive officer.
Please visit our new website at ProtoKinetix.com for more information and to join our email list.
Marietta, Ohio, February 11, 2020
....ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB
KTX) recently filed for patent protection for a new application of its AAGP® molecule. During recent testing at The University of British Columbia, where photo receptors were transplanted into animal models, it was observed that AAGP® may have had a role in protecting xenografts and allografts from immune rejection from the host immune system, thereby helping the graft to survive and mature in the transplant recipient.
Immune rejection, leading to graft versus host disease (GVHD) is a primary concern present in almost all transplants, requiring the use of immunosuppressants such as cyclosporin, tacrolimus and rapamycin.
In addition to filing for patent protection, ProtoKinetix has started a major study at Dalhousie University to examine the effects of AAGP® in transplant medicine.
By protecting this technology, the Company is in a better position to move forward with its research in organ transplantation.
“We are pleased to protect this patent as we can now license the rights to other companies to develop different applications of the AAGP® lead compound,” said Clarence E. Smith, president and chief executive officer.
Please visit our new website at ProtoKinetix.com for more information and to join our email list.
(0)
(0)